A detailed history of Vanguard Group Inc transactions in Kymera Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,822,416 shares of KYMR stock, worth $239 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,822,416
Previous 4,767,050 1.16%
Holding current value
$239 Million
Previous $192 Million 24.88%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

BUY
$29.85 - $39.42 $1.65 Million - $2.18 Million
55,366 Added 1.16%
4,822,416 $144 Million
Q1 2024

May 10, 2024

BUY
$22.9 - $43.57 $17.6 Million - $33.5 Million
769,486 Added 19.25%
4,767,050 $192 Million
Q4 2023

Feb 14, 2024

BUY
$10.97 - $26.84 $793,690 - $1.94 Million
72,351 Added 1.84%
3,997,564 $102 Million
Q3 2023

Nov 14, 2023

BUY
$13.9 - $23.88 $2.53 Million - $4.35 Million
182,125 Added 4.87%
3,925,213 $54.6 Million
Q2 2023

Aug 14, 2023

BUY
$22.4 - $34.92 $205,251 - $319,971
9,163 Added 0.25%
3,743,088 $86.1 Million
Q1 2023

May 15, 2023

BUY
$24.84 - $38.75 $1.83 Million - $2.85 Million
73,618 Added 2.01%
3,733,925 $111 Million
Q4 2022

Feb 10, 2023

BUY
$19.57 - $30.92 $15.6 Million - $24.6 Million
797,130 Added 27.84%
3,660,307 $91.4 Million
Q3 2022

Nov 14, 2022

SELL
$20.91 - $34.27 $241,447 - $395,715
-11,547 Reduced 0.4%
2,863,177 $62.3 Million
Q2 2022

Aug 12, 2022

BUY
$14.13 - $42.55 $522,795 - $1.57 Million
36,999 Added 1.3%
2,874,724 $56.6 Million
Q1 2022

May 13, 2022

SELL
$35.3 - $64.68 $4.22 Million - $7.73 Million
-119,449 Reduced 4.04%
2,837,725 $120 Million
Q4 2021

Feb 14, 2022

BUY
$49.91 - $65.56 $2.77 Million - $3.65 Million
55,600 Added 1.92%
2,957,174 $188 Million
Q3 2021

Nov 12, 2021

BUY
$47.8 - $66.66 $41 Million - $57.2 Million
857,350 Added 41.94%
2,901,574 $170 Million
Q2 2021

Aug 13, 2021

BUY
$31.08 - $51.95 $63.5 Million - $106 Million
2,044,224 New
2,044,224 $99.1 Million

Others Institutions Holding KYMR

About Kymera Therapeutics, Inc.


  • Ticker KYMR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 54,705,800
  • Market Cap $2.71B
  • Description
  • Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunolo...
More about KYMR
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.